THE FACT ABOUT BLOGS FOR PHARMA THAT NO ONE IS SUGGESTING

As points stand, the outlook for Alzheimer’s therapy is a bit more auspicious. Specifically, There have been a surge of pleasure – and an ensuing backwash of scepticism – next the publication of comprehensive final results from Clarity AD, a Stage III confirmatory demo with Eisai and Biogen’s anti-amyloid mAb, lecanemab, in early Alzheimerâ